Alcon (ALC) reported $2.7 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 9.1%. EPS of $0.78 for the same period compares to $0.72 a year ago.
The reported revenue represents a surprise of -0.2% over the Zacks Consensus Estimate of $2.71 billion. With the consensus EPS estimate being $0.79, the EPS surprise was -0.76%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Alcon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Net Sales- Total Surgical- Equipment/other: $277 million compared to the $277.54 million average estimate based on four analysts. The reported number represents a change of +21% year over year.
- Net Sales- Total Surgical- Implantables: $474 million versus $482.1 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4% change.
- Net Sales- Total Surgical: $1.55 billion compared to the $1.56 billion average estimate based on four analysts. The reported number represents a change of +8.6% year over year.
- Net Sales- Total Vision care: $1.16 billion versus the four-analyst average estimate of $1.15 billion. The reported number represents a year-over-year change of +9.8%.
- Net Sales- Total Surgical- Consumables: $794 million versus the four-analyst average estimate of $796.13 million. The reported number represents a year-over-year change of +7.6%.
- Net Sales- Total Vision Care- Contact lenses: $683 million compared to the $687.14 million average estimate based on four analysts. The reported number represents a change of +7.1% year over year.
- Net Sales- Total Vision Care- Ocular health: $474 million compared to the $462.7 million average estimate based on four analysts. The reported number represents a change of +13.9% year over year.
- Net Sales and other revenues- Other revenues: $16 million versus $26.18 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -36% change.
- Net Sales and other revenues- Net Sales: $2.7 billion versus $2.7 billion estimated by three analysts on average.
View all Key Company Metrics for Alcon here>>>
Shares of Alcon have returned +2.6% over the past month versus the Zacks S&P 500 composite's -1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Alcon (ALC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
